Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ phase 2 study of SRK-015 in later-onset spinal muscular atrophy
NL-OMON55820Phase 2Completed
- Sponsor
- Scholar Rock
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of apitegromab in spinal muscular atrophy (SMA) (4 cohorts), sponsored by Scholar Rock. Started Nov 2019; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON55820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55820.